Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveCompleted with results Location: USA

    Persistent Methicillin Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture , protocol number NCT01594827 DASENB10AO, PMEP11K1, JENNIN16K0

    This study will look at the safety and effectiveness of a 28-day course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA) from the respiratory tract of people with CF and persistent MRSA infection.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      7

    • Length of Participation:

      8 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    STOP: Standardised Treatment of Pulmonary Exacerbations Pilot Study , protocol number FLUME13A1

    This study took place at multiple care centres across the US. The goal of the study was to better understand current treatment practices for pulmonary exacerbations and whether the CF Registry can be used for this type of study.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      4

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    IGNITE: Safety and effectiveness of gallium nitrate in adults with cystic fibrosis , protocol number GALLIUM-IP-13

    This study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of IV gallium nitrate in adults with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      5

    • Length of Participation:

      63 days

    Contact us about this clinical Trial >
  • ObservationalCompleted with results Location: USA

    GOAL e2 Lung Clearance Index study in children who have a CFTR gating mutation , protocol number NCT01521338 GOAL-OB-11 Cohort 4

    This study evaluated lung function in young children with CF before and after taking ivacaftor. This study was for children ages 3 to 5 years old who have at least one CFTR gating mutation.

    • Age:

      3 Years to 5 Years

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    GOAL-e2 Expansion Study , protocol number GOAL-OB-11 Expansion

    This is a prospective, multi-centre observational study. This study will look at samples from people with cystic fibrosis who have the R117H and other non-G551D gating CFTR mutations, many of whom are expected to be prescribed ivacaftor during the course of the study. This study is for ages 6 and above.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del of No Copies F506del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    PALS: Aztreonam Inhalation Solution (AZLI) Safety Study in Children with CF and Chronic Pseudomonas Aeruginosa , protocol number Gilead GS_US_205-0160

    This open-label study looked at the safety of Aztreonam Inhalation Solution (Cayston®) given three times daily for three 28-day on/28-day off cycles in children with cystic fibrosis and chronic Pseudomonas aueruginosa (PA) infection in the lower airways.

    • Age:

      Less than 12 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Phase 4 study to monitor the susceptibility of Pseudomonas aeruginosa to aztreonam in people with CF , protocol number Gilead GS-US-205-0128

    This 5-year study took place at multiple care centres across the US. It investigated the susceptibility of Pseudomonas aeruginosa isolates to the anti-infective drug aztreonam.

    • Age:

      1 Year and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 90%

    • Number of Visits:

      5

    • Length of Participation:

      5 years

    Contact us about this clinical Trial >
  • Anti-InflammatoryClosed to enrollment Location: USA

    Phase 2 study of GS-5745 in adults with CF , protocol number Gilead GS-US-404-1808

    This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the anti-inflammatory drug GS-5745 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 80%

    • Number of Visits:

      6

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryClosed to enrollment Location: USA

    Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-001

    This study is taking place at multiple centres across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug JBT-101, as well as how the body processes the drug, in adults with CF.

    • Age:

      18 - 65 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      127 days

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Porcine viral antibody point prevalence study in people with CF taking pancreatic enzymes , protocol number AbbieVie JSPP-12-01

    This study is taking place at multiple care centre across the US. It will look at the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in people with cystic fibrosis who are receiving pancreatic enzyme replacement therapy (PERT).

    • Age:

      2 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      1

    • Length of Participation:

      1 day

    Contact us about this clinical Trial >
  • Displaying results 131-140 (of 178)
     |<  <  9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18  >  >|